CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...